Hypertension - malignant essential
Also known as: Hypertension, High blood pressure, Elevated, Secondary
Methodology & AI Transparency ⓘ
Hypertension - malignant essential Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code I10 in Blood Pressure, Hypertension - malignant essential (also termed Hypertension or High blood pressure) requires segmental arterial Doppler in Hypertension - malignant essential (I10: waveforms) so specialists can calibrate treatment intensity against Ankle-Brachial Index (ABI) [Hypertension - malignant essential I10] benchmarks.
- 2 Real-world patient consensus: Diagnostic registry I10: Hypertension - malignant essential is managed within Blood Pressure (aka Hypertension).
- 3 Typical cash cost range: Workup highlights for Hypertension - malignant essential (I10): segmental arterial Doppler in Hypertension - malignant essential (I10: waveforms).
- 4 Top reported side effects / signs: Objective lab/clinical target for Hypertension - malignant essential: Ankle-Brachial Index (ABI) [Hypertension - malignant essential I10] (1.00 – 1.30 (I10)) and Serum Creatinine & in Hypertension - malignant essential (I10: Potassium).
Ask our AI Specialists anything about Hypertension - malignant essential
What Is Hypertension - malignant essential?
Cataloged under federal diagnostic code I10 in Blood Pressure, Hypertension - malignant essential (also termed Hypertension or High blood pressure) requires segmental arterial Doppler in Hypertension - malignant essential (I10: waveforms) so specialists can calibrate treatment intensity against Ankle-Brachial Index (ABI) [Hypertension - malignant essential I10] benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in blood pressure, Hypertension - malignant essential (I10) involves elevated systemic vascular in Hypertension - malignant essential (I10: resistance). progression correlates with shifts in Ankle-Brachial Index (ABI) [Hypertension - malignant essential I10] (1.00 – 1.30 (I10)).
Common Symptoms & Clinical Signs
- • Presentation of Hypertension - malignant essential (I10): morning occipital headache, in Hypertension - malignant essential (I10: pulsatile tinnitus, or)
- • Secondary Hypertension - malignant essential clinical sign: calf cramping or in Hypertension - malignant essential (I10: claudication triggered by)
- • Symptom flares in Hypertension - malignant essential correlating with Ankle-Brachial Index (ABI) [Hypertension - malignant essential I10] deviation outside 1.00 – 1.30 (I10)
- • Functional blood pressure impact requiring segmental arterial Doppler in Hypertension - malignant essential (I10: waveforms) evaluation (I10)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hypertension - malignant essential Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Hypertension - malignant essential I10] | 1.00 – 1.30 (I10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Hypertension - malignant essential (I10: Potassium) | K+ 4.0 – 4.8 mEq/L (I10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Hypertension - malignant essential I10] | < 15 mg/g (I10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hypertension - malignant essential
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pafolacianine Injection Cytalux • RxCUI RXN-81052138-1785 | Optical Imaging Agent | 80% | $1.3200 | $ 61.96 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hypertension - malignant essential)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Telmisartan plus amlodipine in patients with moderate or severe high blood: What a 1,078-Participant Study Found Telmisartan plus amlodipine provides effective BP lowering at all clinically relevant doses (up to -26.5 mm Hg SBP), and almost 9 out of 10 patients may achieve DBP control. Postgraduate medicine • 2009-03-15 • Randomized Controlled Trial | N = 1,078 | 96/100 | PMID 19332958 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
| New Insights on Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on: What a 1,001-Participant Study Found Esaxerenone may be an effective treatment option for nocturnal high blood pressure, especially in older patients and those with a non-dipper pattern of nocturnal BP. American journal of hypertension • 2021-05-22 • Phase III Randomized Trial | N = 1,001 | 96/100 | PMID 33165570 ↗ |
Hypertension - malignant essential Patient Community & “People Like Me” Threads
Filter Hypertension - malignant essential community threads and patient logs by age, biological sex, dosage, and treatment duration.